文献速递乳腺癌

极年轻女性激素受体阳性乳腺癌的基因组特征

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
PubMed 文献 · Ann Oncol · 2023-01-25

基于SOFT试验中1276例HR+HER2-早期乳腺癌患者的基因组测序,比较<40岁与≥40岁绝经前女性的基因改变频率。年轻组GATA3突变和拷贝数扩增更高,PIK3CA、CDH1、MAP3K1突变更低,HRD特征更常见,且不良预后特征富集,8年DRFI和OS更差。

要点

  • <40岁组GATA3突变19% vs ≥40岁组16%,拷贝数扩增47% vs 26%。
  • <40岁组PIK3CA突变32% vs 47%,CDH1突变3% vs 9%,MAP3K1突变7% vs 12%。
  • 不良预后特征者8年DRFI 84% vs 无特征者94%,OS 88% vs 96%。

核心结论

  • 结果揭示了年轻HR+HER2-早期乳腺癌中富集的基因组改变,为基因组亚组划分提供依据,并突出未来临床试验的优先分子靶点。

研究设计与样本

  • 对SOFT试验中HR+HER2-肿瘤患者进行基因组测序,共1276例(深部靶向测序1258例,年轻年龄病例对照亚组全外显子测序82例)。
  • 比较<40岁与≥40岁绝经前女性的基因组改变频率,并评估其与无远处复发间期(DRFI)和总生存(OS)的关联。

主要发现

  • <40岁组(n=359) vs ≥40岁组(n=917):GATA3突变19% vs 16%,拷贝数扩增47% vs 26%,PIK3CA突变32% vs 47%,CDH1突变3% vs 9%,MAP3K1突变7% vs 12%。
  • <40岁组 vs ≥40岁组:HRD特征27% vs 21%,PIK3CA突变伴拷贝数扩增23% vs 11%。
  • HRD特征、PIK3CA突变伴拷贝数扩增、拷贝数扩增与更差的DRFI和OS显著相关。
  • 不良预后特征在<35岁、35-39岁、≥40岁患者中分别占72%、54%、40%。
  • 不良预后特征组(n=584,46%) vs 无特征组(n=692,54%):8年DRFI 84% vs 94%,OS 88% vs 96%;<40岁组8年DRFI 74% vs 85%,OS 80% vs 93%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained. PATIENTS AND METHODS: Genomic sequencing was applied to HR+HER2- tumours from patients enrolled in the Suppression of Ovarian Function Trial (SOFT) to determine genomic drivers that are enriched in young premenopausal women. Genomic alterations were characterised using next-generation sequencing from a subset of 1276 patients (deep targeted sequencing, n = 1258; whole-exome sequencing in a young-age, case-control subsample, n = 82). We defined copy number (CN) subgroups and assessed for features suggestive of homologous recombination deficiency (HRD). Genomic alteration frequencies were compared between young premenopausal women (<40 years) and older premenopausal women (≥40 years), and assessed for associations with distant recurrence-free interval (DRFI) and overall survival (OS). RESULTS: Younger women (<40 years, n = 359) compared with older women (≥40 years, n = 917) had significantly higher frequencies of mutations in GATA3 (19% versus 16%) and CN amplifications (CNAs) (47% versus 26%), but significantly lower frequencies of mutations in PIK3CA (32% versus 47%), CDH1 (3% versus 9%), and MAP3K1 (7% versus 12%). Additionally, they had significantly higher frequencies of features suggestive of HRD (27% versus 21%) and a higher proportion of PIK3CA mutations with concurrent CNAs (23% versus 11%). Genomic features suggestive of HRD, PIK3CA mutations with CNAs, and CNAs were associated with significantly worse DRFI and OS compared with those without these features. These poor prognostic features were enriched in younger patients: present in 72% of patients aged <35 years, 54% aged 35-39 years, and 40% aged ≥40 years. Poor prognostic features [n = 584 (46%)] versus none [n = 692 (54%)] had an 8-year DRFI of 84% versus 94% and OS of 88% versus 96%. Younger women (<40 years) had the poorest outcomes: 8-year DRFI 74% versus 85% and OS 80% versus 93%, respectively. CONCLUSION: These results provide insights into genomic alterations that are enriched in young women with HR+HER2- EBC, provide rationale for genomic subgrouping, and highlight priority molecular targets for future clinical trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Luen SJ, Viale G, Nik-Zainal S, et al. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol. 2023. PMID: 36709040. doi:10.1016/j.annonc.2023.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。